At least one line of therapy including a fluoropyrimidine and platinum regimen for advanced disease. Patients with unknown tumor PD-L1 CPS score, those with CPS ≥ 10%, and patients with MSI-High or MMR deficient tumors were required to have progression on at least one line of prior therapy with an ICI containing regimen. The gene discussed is CD274; the disease is neoplasm.